💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Odesivimab

CHEMBL4298188 Phase 4 Đã phê duyệt Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A monoclonal antibody targeting the glycoprotein of Ebola virus (Zaire ebolavirus), used as part of a combination antibody therapy to treat Ebola virus disease. It binds to the viral surface protein to prevent the virus from entering human cells.

Cơ chế tác dụng

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A monoclonal antibody targeting the glycoprotein of Ebola virus (Zaire ebolavirus), used as part of a combination antibody therapy to treat Ebola virus disease. It binds to the viral surface protein to prevent the virus from entering human cells.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Odesivimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298188. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.